Ustekinumab – Medxy AI

Evaluating Dose Intensification Strategies for Ustekinumab in Crohn’s Disease: Insights from the REScUE Trial

By MedXY 07/13/2026

The REScUE study compared two ustekinumab dosing intensification regimens after secondary loss of response in Crohn’s disease, finding no superiority of more frequent dosing regarding steroid-free remission at 48 weeks.

Clinical Updates news Public Health Specialties

The Dawn of the “No-Clinical-Trial” Era for Biosimilars: FDA’s Historic Ustekinumab Approval Shift

By MedXY 09/06/2025

The US FDA's unprecedented exemption of clinical efficacy studies for a ustekinumab biosimilar marks a transformative regulatory milestone, reshaping biosimilar development, market dynamics, and patient access worldwide.

Clinical Updates Gastroenterology news Specialties

Early Control of Ulcerative Colitis and Its Impact on Long-Term Outcomes: Insights from the UNIFI Phase 3 Study

By MedXY 08/26/2025

Achieving disease clearance early after induction therapy with ustekinumab in ulcerative colitis patients predicts sustained clinical remission, symptom control, and improved quality of life over four years.